

# Ashley N. Wallace, BS CCRC

## **Dawes Fretzin Clinical Research Group, LLC**

7910 North Shadeland Avenue  
Indianapolis, Indiana 46250  
Phone (317) 516-5030 Ext. 102  
Fax (317) 516-5031  
Email: [awallace@ecommunity.com](mailto:awallace@ecommunity.com)

## **Dawes Fretzin Dermatology Group, LLC**

7910 North Shadeland Avenue  
Indianapolis, Indiana 46250  
Phone (317) 516-5030 Ext. 102  
Fax (317) 516-5031

---

## **Education**

Ball State University, (Muncie, IN)  
Bachelor of Science, Biology, May 2010

Pendleton Heights High School (Pendleton, IN)  
Summa Cum Laude Diploma, 2006

## **Professional Experience**

**Dawes Fretzin Clinical Research Group, LLC** (Indianapolis, IN)  
*Director of Clinical Research, August 2017-Present*

**Dawes Fretzin Clinical Research Group, LLC** (Indianapolis, IN)  
*Study Coordinator, July 2012-Present*

**Dawes Fretzin Dermatology Group, LLC** (Indianapolis, IN)  
*Research Assistant, July 2012-August 2017*

**IUPUI – Infectious Disease Department** (Indianapolis, IN)  
*Research Technician, May 2010-July 2012*

**St. John's Hospital** (Anderson, IN)  
*EMT, June 2007-May 2010*

**St. John's Hospital** (Anderson, IN)  
*Emergency Room Secretary, June 2007-May 2010*

**Central Indiana Orthopedics** (Anderson, IN)  
*Office Assistant, August 2009- May 2010*

*Ashley  
Wallace  
16 JUN 2026*

## **License/Certifications**

EMT-Basic 4223-7952  
CITI GCP Certification  
ACLS Certification  
TB Certification  
IATA Certification  
ACRP CCRC Certification  
BLS Certification

# Ashley N. Wallace, BS CCRC

## Presentations/Posters

The American Academy of Dermatology Meeting. J. Clay Cather, A. Potts Bleakman, A. Naegeli, J. Ling Poon, A. Wallace, K. Hollister, S. Fretzin. **Patients' Perspective on the Impact of Moderate-To-Severe Genital Psoriasis.** March, 2017

## Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

| Sponsor         | Protocol      | Indication             | Role | Phase | Date of COV |
|-----------------|---------------|------------------------|------|-------|-------------|
| Warner Chilcott | PR-10411      | Acne                   | SC   | 2     | 09-Jan-13   |
| Taro            | CLBG1210      | Acne                   | SC   | 3     | 04-Feb-14   |
| Cipher          | RAN.13.01     | Acne                   | SC   | 3     | 13-Mar-14   |
| Allergan        | 225678-007    | Acne                   | SC   | 3     | 21-Jan-15   |
| Valeant         | V01-123A-501  | Acne                   | SC   | 1b    | 14-Mar-17   |
| Foamix          | FX2014-05     | Acne                   | SC   | 3     | 27-Apr-17   |
| Valeant         | V01-121A-302  | Acne                   | SC   | 3     | 09-May-17   |
| Elorac          | EL-1006-01-01 | Acne                   | SC   | 2     | 06-Jun-17   |
| Ranbaxy         | ABS1517LT     | Acne                   | SC   | 4     | 24-Apr-18   |
| Dr. Reddy's     | DFD-03-CD-006 | Acne                   | SC   | 2     | 31-Jul-18   |
| Foamix          | FX2017-22     | Acne                   | SC   | 2     | 28-Sep-18   |
| Bausch Health   | V01-121A-501  | Acne                   | SC   | 1b    | 01-Oct-19   |
| Bausch Health   | V01-121A-302  | Acne                   | SC   | 3     | 01-Mar-21   |
| UPENN           | Acne          | Acne                   | SC   | 4     | 16-Apr-25   |
| Sanofi          | VBE00001      | Acne                   | SC   | 1/2   | 24-Feb-26   |
| Aczone          | 225678-007    | Acne                   | SC   | 3     | 01-Mar-16   |
| Actavis         | 094-3153-301  | Actinic Keratosis      | SC   | 4     | 11-Jun-14   |
| LEO             | LP0105-1012   | Actinic Keratosis      | SC   | 1/2   | 13-Aug-14   |
| LEO             | LP0084-1148   | Actinic Keratosis      | SC   | 2     | 15-Sep-15   |
| Perrigo         | PRG-NY-14-019 | Actinic Keratosis      | SC   | 3     | 14-Dec-15   |
| Actavis         | 094-8151-301  | Actinic Keratosis      | SC   | 4     | 17-Dec-15   |
| Actavis         | 094-8152-301  | Actinic Keratosis      | SC   | 4     | 22-May-17   |
| LEO             | LP0105-1032   | Actinic Keratosis      | SC   | 3     | 13-Oct-17   |
| Athenex         | KX01-AK-004   | Actinic Keratosis      | SC   | 3     | 21-Nov-19   |
| Merck           | A-11107       | Allergen Immunotherapy | SC   | OBS   | 09-Apr-13   |
| Pfizer          | B7931005      | Alopecia Areata        | SC   | 2a    | 12-Mar-19   |
| DRG Abacus      | 7785          | Alopecia Areata        | SC   | OBS   | 01-Sep-19   |
| Evidera         | EVA-20417-00  | Alopecia Areata        | SC   | OBS   | 11-Mar-20   |
| Pfizer          | B7981015      | Alopecia Areata        | SC   | 2b/3  | 03-Aug-21   |
| Reistone        | RSJ10521      | Alopecia Areata        | SC   | 2     | 26-Aug-21   |
| AnaptysBio      | ANB030-201    | Alopecia Areata        | SC   | 2     | 22-Mar-23   |
| Horizon         | HZNP-DAX-201  | Alopecia Areata        | SC   | 2a    | 28-Mar-23   |
| Concert         | CP543.3001    | Alopecia Areata        | SC   | 3     | 13-Jul-23   |

# Ashley N. Wallace, BS CCRC

| Sponsor       | Protocol      | Indication            | Role | Phase | Date of COV |
|---------------|---------------|-----------------------|------|-------|-------------|
| Arena         | APD334-205    | Alopecia Areata       | SC   | 2     | 30-Aug-23   |
| Pfizer        | B7981031      | Alopecia Areata       | SC   | 1     | 17-Oct-23   |
| Inmagene      | IMG-007-002   | Alopecia Areata       | SC   | 1b/2a | 28-Jun-24   |
| Pfizer        | B7981032      | Alopecia Areata       | SC   | 3     | 01-Aug-24   |
| Aslan         | ASLAN003-004  | Alopecia Areata       | SC   | 2a    | 12-Aug-24   |
| Sanofi        | DRI18180      | Alopecia Areata       | SC   | 2     | 10-Feb-25   |
| Lilly         | I4V-MC-JAIR   | Alopecia Areata       | SC   | 3     | 13-Mar-25   |
| Adelphi       | AG9909        | Alopecia Areata       | SC   | OBS   | 15-Apr-26   |
| Concert       | CP543.5001    | Alopecia Areata       | SC   | 3     | 28-Apr-26   |
| DrenBio       | DR-01-AIM-001 | Alopecia Areata       | SC   | 1b    | ONGOING     |
| HCW Biologics | HCWALO101     | Alopecia Areata       | SC   | 1b    | ONGOING     |
| Lilly         | I4V-MC-JAIO   | Alopecia Areata       | SC   | 3     | ONGOING     |
| Sun Pharma    | CP543.3101    | Alopecia Areata       | SC   | 3     | ONGOING     |
| Abbvie        | M24-725       | Alopecia Areata       | SC   | 3     | ONGOING     |
| CorEvitas     | AA-565        | Alopecia Areata       | SC   | OBS   | ONGOING     |
| Pfizer        | B7981027      | Alopecia Areata       | SC   | 3     | ONGOING     |
| Pfizer        | B7981028      | Alopecia Areata       | SC   | 3     | ONGOING     |
| Pfizer        | B7981094      | Alopecia Areata       | SC   | 3     | ONGOING     |
| Pfizer        | B7981110      | Alopecia Areata       | SC   | 3     | ONGOING     |
| Pelage        | PP405-2001    | Androgenetic Alopecia | SC   | 2a    | 24-Nov-25   |
| Pelage        | PP405-2002    | Androgenetic Alopecia | SC   | 2/3   | ONGOING     |
| Veradermics   | 250-13951-302 | Androgenetic Alopecia | SC   | 3     | ONGOING     |
| Veradermics   | 250-13951-306 | Androgenetic Alopecia | SC   | 3     | ONGOING     |
| GSK           | SAS115358     | Asthma                | SC   | 4     | 30-Oct-13   |
| GSK           | SAS115359     | Asthma                | SC   | 4     | 01-May-14   |
| Anacor        | AN2728-AD-203 | Atopic Dermatitis     | SC   | 2a    | 21-Jan-13   |
| Novartis      | CBPR277X2101  | Atopic Dermatitis     | SC   | 1     | 13-Feb-13   |
| Anacor        | AN2728-AD-302 | Atopic Dermatitis     | SC   | 3     | 11-Aug-15   |
| Anacor        | AN2728-AD-303 | Atopic Dermatitis     | SC   | 3     | 11-Nov-15   |
| Regeneron     | R668-AD-1314  | Atopic Dermatitis     | SC   | 2     | 10-Dec-15   |
| Regeneron     | R668-AD-1334  | Atopic Dermatitis     | SC   | 3     | 31-May-16   |
| MedImmune     | D5240C00001   | Atopic Dermatitis     | SC   | 2a    | 22-Sep-16   |
| Chugai        | CIM003JG      | Atopic Dermatitis     | SC   | 2     | 20-Oct-16   |
| Regeneron     | R668-AD-1415  | Atopic Dermatitis     | SC   | 3     | 08-Feb-17   |
| GSK           | 203121        | Atopic Dermatitis     | SC   | 2     | 29-Mar-17   |
| Pfizer        | B7451006      | Atopic Dermatitis     | SC   | 2b    | 26-Apr-17   |
| Regeneron     | R668-AD-1225  | Atopic Dermatitis     | SC   | 3     | 27-Sep-17   |
| LEO           | LP0156-1294   | Atopic Dermatitis     | SC   | OBS   | 24-Oct-17   |
| GSK           | 205050        | Atopic Dermatitis     | SC   | 2a    | 11-Jan-18   |
| Sun Pharma    | 71542612      | Atopic Dermatitis     | SC   | 3     | 15-Feb-18   |
| Regeneron     | R668-AD-1607  | Atopic Dermatitis     | SC   | 1b    | 10-Apr-18   |
| Incyte        | INCB18424-206 | Atopic Dermatitis     | SC   | 2     | 18-May-18   |
| Novan         | NI-AD101      | Atopic Dermatitis     | SC   | 1b    | 25-Jun-18   |
| Regeneron     | R668-AD-1526  | Atopic Dermatitis     | SC   | 3     | 19-Jul-18   |

# Ashley N. Wallace, BS CCRC

| Sponsor           | Protocol         | Indication        | Role | Phase | Date of COV |
|-------------------|------------------|-------------------|------|-------|-------------|
| Dermavant         | RVT-502-2001     | Atopic Dermatitis | SC   | 2     | 01-Aug-18   |
| Dermavant         | RVT-501-2007     | Atopic Dermatitis | SC   | 1b    | 03-Aug-18   |
| Pfizer            | C0341001         | Atopic Dermatitis | SC   | 1     | 09-Oct-18   |
| Lilly             | I4V-MC-JAHL      | Atopic Dermatitis | SC   | 3     | 06-Dec-18   |
| Pfizer            | B7451012         | Atopic Dermatitis | SC   | 3     | 23-May-19   |
| Pfizer            | B7451013         | Atopic Dermatitis | SC   | 3     | 27-Jun-19   |
| Dermira           | DRM06-AD01       | Atopic Dermatitis | SC   | 2b    | 30-Jul-19   |
| Kiniksa           | KPL-716-C001     | Atopic Dermatitis | SC   | 1b    | 20-Sep-19   |
| Asana             | ASN002AD-201     | Atopic Dermatitis | SC   | 2b    | 25-Sep-19   |
| LEO               | LP0162-1326      | Atopic Dermatitis | SC   | 3     | 15-Oct-19   |
| Galapagos         | MOR106-CL-204    | Atopic Dermatitis | SC   | 2     | 28-Oct-19   |
| Arcutis           | ARQ-151-212      | Atopic Dermatitis | SC   | 2     | 10-Dec-19   |
| Qurient           | Q301-AD-P2-US002 | Atopic Dermatitis | SC   | 2     | 07-Jan-20   |
| Ralexar           | ALX-101-ATOP-204 | Atopic Dermatitis | SC   | 2     | 27-Jan-20   |
| Asana             | ASN002AD-201-EXT | Atopic Dermatitis | SC   | 2     | 10-Mar-20   |
| Pfizer            | B7451036         | Atopic Dermatitis | SC   | 3     | 21-May-20   |
| LEO               | LP0133-1181      | Atopic Dermatitis | SC   | 1     | 25-Jun-20   |
| Lilly             | I4V-MC-JAIW      | Atopic Dermatitis | SC   | 3     | 03-Aug-20   |
| Lilly             | I4V-MC-JAIX      | Atopic Dermatitis | SC   | 3     | 03-Aug-20   |
| Kyowa Hakko Kirin | 4083-006         | Atopic Dermatitis | SC   | 2     | 15-Sep-20   |
| Lilly             | I4V-MC-JAHN      | Atopic Dermatitis | SC   | 3     | 21-Sep-20   |
| Pfizer            | B7451014         | Atopic Dermatitis | SC   | 3     | 19-Nov-20   |
| Regeneron         | R668-AD-1434     | Atopic Dermatitis | SC   | 3     | 09-Dec-20   |
| Incyte            | INCB18424-303    | Atopic Dermatitis | SC   | 3     | 28-Jan-21   |
| Abbvie            | M16-046          | Atopic Dermatitis | SC   | 3b    | 01-Feb-21   |
| Xbiotech          | 2019-PT046       | Atopic Dermatitis | SC   | 2     | 21-Feb-21   |
| Sanofi            | LPS15496         | Atopic Dermatitis | SC   | OBS   | 27-Apr-21   |
| Sanofi            | OBS15333         | Atopic Dermatitis | SC   | OBS   | 27-Apr-21   |
| Aclaris           | ATI-1777-AD-201  | Atopic Dermatitis | SC   | 2a    | 23-Jun-21   |
| Rapt              | RPT193-01        | Atopic Dermatitis | SC   | 1     | 26-Jul-21   |
| Pfizer            | B7451050         | Atopic Dermatitis | SC   | 3b    | 12-Aug-21   |
| BMX               | BMX-DERM-01      | Atopic Dermatitis | SC   | 1/2   | 24-Aug-21   |
| Pfizer            | C3941002         | Atopic Dermatitis | SC   | 2a    | 15-Nov-21   |
| Janssen           | 77474462ADM2003  | Atopic Dermatitis | SC   | 2a    | 06-Apr-22   |
| Abbvie            | M19-850          | Atopic Dermatitis | SC   | 3b    | 21-Apr-22   |
| Janssen           | 77474462ADM2001  | Atopic Dermatitis | SC   | 3     | 16-May-22   |
| Lilly             | F1P-MC-KFAD      | Atopic Dermatitis | SC   | 1     | 21-Jun-22   |
| BMS               | IM011-005        | Atopic Dermatitis | SC   | 2     | 01-Aug-22   |
| Dermira           | DRM06-AD17       | Atopic Dermatitis | SC   | 3     | 24-Aug-22   |
| BMS               | IM018-005        | Atopic Dermatitis | SC   | 2     | 20-Sep-22   |
| Celgene           | CC-93538-AD-001  | Atopic Dermatitis | SC   | 2     | 07-Dec-22   |
| Connect           | CBP-201-WW004    | Atopic Dermatitis | SC   | 3     | 30-Dec-22   |
| LEO               | LP0162-1337      | Atopic Dermatitis | SC   | 3     | 27-Jan-23   |
| Galderma          | RD.06.SPR.118161 | Atopic Dermatitis | SC   | 3     | 13-Feb-23   |

# Ashley N. Wallace, BS CCRC

| Sponsor           | Protocol                | Indication        | Role | Phase | Date of COV |
|-------------------|-------------------------|-------------------|------|-------|-------------|
| GSK               | 215253                  | Atopic Dermatitis | SC   | 1b    | 13-Jun-23   |
| Arcutis           | ARQ-151-313             | Atopic Dermatitis | SC   | 3     | 11-Jul-23   |
| Pfizer            | C3941005                | Atopic Dermatitis | SC   | 2b    | 01-Aug-23   |
| OM1               | DataDerm                | Atopic Dermatitis | SC   | OBS   | 19-Aug-23   |
| Evomune           | EVO101-AD001            | Atopic Dermatitis | SC   | 2a    | 29-Aug-23   |
| Alumis            | ESK-001-006             | Atopic Dermatitis | SC   | 2     | 08-Sep-23   |
| DermTech          | 20-03                   | Atopic Dermatitis | SC   | 4     | 24-Oct-23   |
| Acrotech          | MEDI-MM36-301           | Atopic Dermatitis | SC   | 3     | 20-Nov-23   |
| Evidera           | EVA-25835               | Atopic Dermatitis | SC   | OBS   | 15-Dec-23   |
| Galderma          | RD.06.SPR.118380        | Atopic Dermatitis | SC   | 2     | 21-Dec-23   |
| Aslan             | ASLAN004-003            | Atopic Dermatitis | SC   | 2b    | 04-Jan-24   |
| Aclaris           | ATI-1777-AD-202         | Atopic Dermatitis | SC   | 2b    | 06-Feb-24   |
| Alumis            | ESK-001-007             | Atopic Dermatitis | SC   | 2     | 13-Feb-24   |
| TrialSpark        | ASN008-201              | Atopic Dermatitis | SC   | 2     | 14-Feb-24   |
| Cara              | CR845-310501            | Atopic Dermatitis | SC   | 3     | 07-Mar-24   |
| Kymab             | KY1005-CT05             | Atopic Dermatitis | SC   | 2b    | 02-May-24   |
| Rapt              | RPT193-02               | Atopic Dermatitis | SC   | 2     | 07-Jun-24   |
| Incyte            | INCB18424-305           | Atopic Dermatitis | SC   | 3     | 26-Jun-24   |
| Acrotech          | MEDI-MM36-302           | Atopic Dermatitis | SC   | 3     | 16-Jul-24   |
| Biosion           | BSI-045B-002            | Atopic Dermatitis | SC   | 2a    | 18-Jul-24   |
| Abbvie            | M16-049                 | Atopic Dermatitis | SC   | 2b    | 29-Oct-24   |
| Abbvie            | M23-696                 | Atopic Dermatitis | SC   | 3b/4  | 29-Oct-24   |
| Taro              | RXLC-2118               | Atopic Dermatitis | SC   | 4     | 04-Dec-24   |
| Incyte            | INCB18424-902           | Atopic Dermatitis | SC   | 4     | 05-Feb-25   |
| Pfizer            | B7451015                | Atopic Dermatitis | SC   | 3     | 25-Mar-25   |
| Lilly             | J2T-MC-KGBO             | Atopic Dermatitis | SC   | 3b    | 01-Apr-25   |
| Lilly             | J2T-MC-KGBP             | Atopic Dermatitis | SC   | 3b    | 02-Apr-25   |
| Dermira           | DRM06-AD07              | Atopic Dermatitis | SC   | 3     | 09-Apr-25   |
| Amgen             | 20210144                | Atopic Dermatitis | SC   | 3     | 29-Apr-25   |
| Galderma          | RD.06.SPR.118126        | Atopic Dermatitis | SC   | 2     | 11-Jun-25   |
| Abbvie            | M24-601                 | Atopic Dermatitis | SC   | 3b/4  | 12-Jun-25   |
| LEO               | LP0145-2240             | Atopic Dermatitis | SC   | 2b    | 25-Jun-25   |
| Apollo            | AP43CP03                | Atopic Dermatitis | SC   | 2     | 04-Nov-25   |
| CastleBio Science | CBI_2021_ISD_DevVal_001 | Atopic Dermatitis | SC   | 4     | 02-Dec-25   |
| Galderma          | RD.06.SPR.118163        | Atopic Dermatitis | SC   | 3     | 20-Jan-26   |
| Sanofi            | EFC17561                | Atopic Dermatitis | SC   | 3     | 03-Feb-26   |
| Abbvie            | M16-045                 | Atopic Dermatitis | SC   | 3     | 04-Feb-26   |
| Amgen             | 20210145                | Atopic Dermatitis | SC   | 3     | 26-Feb-26   |
| TARGET-DERM       | TARGET-DERM             | Atopic Dermatitis | SC   | 4     | 06-Apr-26   |
| Janssen           | 95475939ADM2001         | Atopic Dermatitis | SC   | 2b    | 12-May-26   |
| Roche             | CS45943                 | Atopic Dermatitis | SC   | 2     | N/A         |
| Attovia           | ATTO-3712-101           | Atopic Dermatitis | SC   | 1     | ONGOING     |
| Enveda            | ENV-294-202             | Atopic Dermatitis | SC   | 2b    | ONGOING     |
| Lilly             | J2T-MC-B002             | Atopic Dermatitis | SC   | 4     | ONGOING     |

# Ashley N. Wallace, BS CCRC

| Sponsor     | Protocol                 | Indication                         | Role | Phase | Date of COV |
|-------------|--------------------------|------------------------------------|------|-------|-------------|
| Organon     | OG0505-3104              | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Triveni Bio | TRIV-509-101             | Atopic Dermatitis                  | SC   | 2a    | ONGOING     |
| Triveni Bio | TRIV-573-101             | Atopic Dermatitis                  | SC   | 2     | ONGOING     |
| Abbvie      | M16-047                  | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Abbvie      | M17-380                  | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Aclaris     | ATI-045-AD-201           | Atopic Dermatitis                  | SC   | 2b    | ONGOING     |
| Amgen       | 20210146                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Anacor      | AN2728-AD-301-302-POST01 | Atopic Dermatitis                  | SC   | OBS   | ONGOING     |
| Apogee      | APG777-301               | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Apollo      | AP43CP04                 | Atopic Dermatitis                  | SC   | 2b    | ONGOING     |
| CorEvitas   | AD-550                   | Atopic Dermatitis                  | SC   | 4     | ONGOING     |
| Corrona     | Corrona-AD-550           | Atopic Dermatitis                  | SC   | 4     | ONGOING     |
| Galderma    | SPR207806                | Atopic Dermatitis                  | SC   | OBS   | ONGOING     |
| Janssen     | 95597528ADM2001          | Atopic Dermatitis                  | SC   | 2b    | ONGOING     |
| Lilly       | J2T-MC-KGCE              | Atopic Dermatitis                  | SC   | 4     | ONGOING     |
| Pfizer      | B7451023                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Pfizer      | B7451031                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Pfizer      | C4531002                 | Atopic Dermatitis                  | SC   | 2     | ONGOING     |
| Pfizer      | C4531005                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Roche       | CS45570                  | Atopic Dermatitis                  | SC   | 2     | ONGOING     |
| Sanofi      | EFC17599                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Sanofi      | EFC17600                 | Atopic Dermatitis                  | SC   | 3     | ONGOING     |
| Sanofi      | LTS17367                 | Atopic Dermatitis                  | SC   | 2/3   | ONGOING     |
| Brickell    | BBI-4000-CL-301          | Axillary Hyperhidrosis             | SC   | 3     | 11-Aug-21   |
| Akari       | AK802                    | Bullous Pemphigoid                 | SC   | 3     | 08-Sep-22   |
| AstraZenaca | D325AC00002              | Bullous Pemphigoid                 | SC   | 3     | 31-Aug-23   |
| Asana       | ASN002AD-202             | Chronic Hand Eczema                | SC   | 2     | 22-Jun-20   |
| Arcutis     | ARQ-252-205              | Chronic Hand Eczema                | SC   | 1/2b  | 07-Aug-20   |
| Evommune    | EVO756-CIU001            | Chronic Inducible Urticaria        | SC   | 2a    | 20-Jun-25   |
| Celldex     | CDX0159-07               | Chronic Inducible Urticaria        | SC   | 2     | 25-Nov-25   |
| Menlo       | MTI-117                  | Chronic Pruritus of Unknown Origin | SC   | 2     | 29-May-20   |
| Sanofi      | EFC16973                 | Chronic Pruritus of Unknown Origin | SC   | 3     | 13-Nov-24   |
| Novartis    | CLOU064R12301            | Chronic Pruritus of Unknown Origin | SC   | 3     | ONGOING     |
| Galderma    | SPR207913                | Chronic Pruritus of Unknown Origin | SC   | 2     | ONGOING     |
| Novartis    | CQGE031C2201             | Chronic Spontaneous Urticaria      | SC   | 2b    | 29-Jun-16   |
| Genentech   | ML29510                  | Chronic Spontaneous Urticaria      | SC   | 4     | 27-Jun-17   |
| Novartis    | CQGE031C2302             | Chronic Spontaneous Urticaria      | SC   | 3     | 30-Sep-22   |
| Novartis    | CQGE031C2302E1           | Chronic Spontaneous Urticaria      | SC   | 3b    | 25-Oct-22   |
| Celldex     | CDX0159-02               | Chronic Spontaneous Urticaria      | SC   | 1     | 10-Jan-23   |
| Evidera     | EVA-32391-01             | Chronic Spontaneous Urticaria      | SC   | OBS   | 13-Mar-23   |
| Amgen       | 20190194                 | Chronic Spontaneous Urticaria      | SC   | 2b    | 20-Apr-23   |
| Celldex     | CDX0159-06               | Chronic Spontaneous Urticaria      | SC   | 2     | 07-Nov-23   |
| Escient     | EP-262-201               | Chronic Spontaneous Urticaria      | SC   | 2     | 26-Mar-25   |
| InflaRX     | INF904-P2.1              | Chronic Spontaneous Urticaria      | SC   | 2a    | 04-Dec-25   |

# Ashley N. Wallace, BS CCRC

| ponsor               | Protocol              | Indication                        | Role | Phase | Date of COV |
|----------------------|-----------------------|-----------------------------------|------|-------|-------------|
| Blueprint Medicines  | BLU-808-1201          | Chronic Spontaneous Urticaria     | SC   | 2     | ONGOING     |
| Celldex              | CDX0159-12            | Chronic Spontaneous Urticaria     | SC   | 3     | ONGOING     |
| Celldex              | CDX0159-17            | Chronic Spontaneous Urticaria     | SC   | 3b    | ONGOING     |
| Jasper Therapeutics  | JSP-CP-011            | Chronic Spontaneous Urticaria     | SC   | 2a    | ONGOING     |
| Jasper Therapeutics  | JSP-CP-014            | Chronic Spontaneous Urticaria     | SC   | 2     | ONGOING     |
| Novartis             | CLOU064AUS04          | Chronic Spontaneous Urticaria     | SC   | OBS   | ONGOING     |
| Novartis             | CQVA149A2336          | COPD                              | SC   | 3     | 07-May-14   |
| GSK                  | CTT116855             | COPD                              | SC   | 3     | 16-Jun-15   |
| GSK                  | LPL100601             | Coronary Heart Disease            | SC   | 3     | 13-Aug-13   |
| Pfizer               | A6261008              | Cutaneous Lupus Erythematosus     | SC   | 3     | 26-Feb-14   |
| Janssen              | NOCOMPOUNDLUN0001     | Cutaneous Lupus Erythematosus     | SC   | OBS   | 29-Oct-14   |
| Biogen               | 230LE201              | Cutaneous Lupus Erythematosus     | SC   | 2     | 22-Jul-20   |
| Gilead               | GS-US-497-5888        | Cutaneous Lupus Erythematosus     | SC   | 1b    | 29-Nov-22   |
| Biogen               | 230LE301              | Cutaneous Lupus Erythematosus     | SC   | 3     | 31-Oct-23   |
| Biogen               | 230LE305              | Cutaneous Lupus Erythematosus     | SC   | 3     | 31-Oct-23   |
| Merck                | MS200569-0003         | Cutaneous Lupus Erythematosus     | SC   | 2     | 16-Jan-25   |
| Horizon              | HZNP-DAX-202          | Cutaneous Lupus Erythematosus     | SC   | 2     | 21-Nov-25   |
| Merck                | MS200569-0048         | Cutaneous Lupus Erythematosus     | SC   | 1     | 28-Jan-26   |
| Gilead               | GS-US-497-6486        | Cutaneous Lupus Erythematosus     | SC   | 2a    | 19-May-26   |
| Merck                | MS504908_0008         | Cutaneous Lupus Erythematosus     | SC   | 3     | ONGOING     |
| Ventus               | VENT-03-201           | Cutaneous Lupus Erythematosus     | SC   | 2a    | ONGOING     |
| Nflection            | NFX-179-NFI-202       | Cutaneous Neurofibroma            | SC   | 2     | 16-Oct-23   |
| Regeneron            | R2810-ONC-2251        | Cutaneous Squamous Cell Carcinoma | SC   | 3     | 28-May-26   |
| CastleBio Science    | CBI_2019_cSCC_PVS_001 | Cutaneous Squamous Cell Carcinoma | SC   | 4     | ONGOING     |
| Soligenix            | HPN-CTCL-01           | Cutaneous T-Cell Lymphoma         | SC   | 3     | 24-Feb-21   |
| Elorac               | EL-1007-01-01         | Cutaneous T-Cell Lymphoma         | SC   | 3     | 20-Oct-22   |
| Soligenix            | HPN-CTCL-03-EUR       | Cutaneous T-Cell Lymphoma         | SC   | 3     | ONGOING     |
| Takeda               | TAK-875_306           | Diabetes - Type 2                 | SC   | 3     | 26-Feb-14   |
| Evidera              | EVA-16679             | Genital Psoriasis                 | SC   | OBS   | 01-Jun-15   |
| Lilly                | I1F-MC-RHBQ           | Genital Psoriasis                 | SC   | 3     | 17-May-18   |
| Celgene              | CC-10004-PSOR-025     | Genital Psoriasis                 | SC   | 3     | 27-Apr-22   |
| AnaptysBio           | ANB019-002            | GPP                               | SC   | 2a    | 20-Oct-20   |
| AnaptysBio           | ANB019-401            | GPP/PPP                           | SC   | 3     | 02-Mar-23   |
| Regeneron            | R668-AD-1924          | Hand/Foot Dermatitis              | SC   | 3     | 22-Feb-23   |
| Lilly                | J2T-MC-KGCD           | Hand/Foot Dermatitis              | SC   | 3b    | ONGOING     |
| CSL Bering           | CSI324-2001           | Hidradenitis Suppurativa          | SC   | 2     | 10-May-14   |
| AstraZenaca          | D5440C00001           | Hidradenitis Suppurativa          | SC   | 2a    | 10-Dec-14   |
| Novartis             | CCJM112X2202          | Hidradenitis Suppurativa          | SC   | 2     | 29-Mar-17   |
| Abbvie               | H13-147               | Hidradenitis Suppurativa          | SC   | OBS   | 25-Feb-20   |
| Xbiotech             | 2019-PT047            | Hidradenitis Suppurativa          | SC   | 2     | 21-Feb-21   |
| ChemoCentryx         | CL016_168             | Hidradenitis Suppurativa          | SC   | 2     | 11-May-21   |
| Pfizer               | C2501007              | Hidradenitis Suppurativa          | SC   | 2a    | 15-Feb-22   |
| Abbvie               | M20-040               | Hidradenitis Suppurativa          | SC   | 2     | 15-Mar-22   |
| Boehringer Ingelheim | 1368-0052             | Hidradenitis Suppurativa          | SC   | 2a    | 29-Mar-22   |

# Ashley N. Wallace, BS CCRC

| Sponsor              | Protocol        | Indication               | Role | Phase | Date of COV |
|----------------------|-----------------|--------------------------|------|-------|-------------|
| Novartis             | CAIN457M2302    | Hidradenitis Suppurativa | SC   | 2/3   | 31-Oct-22   |
| Boehringer Ingelheim | 1368-0067       | Hidradenitis Suppurativa | SC   | 2     | 31-Jan-23   |
| Janssen              | 77474462HDS2001 | Hidradenitis Suppurativa | SC   | 2     | 10-Feb-23   |
| Moonlake             | M1095-HS-201    | Hidradenitis Suppurativa | SC   | 2     | 02-Oct-23   |
| Acelyrin             | 21102           | Hidradenitis Suppurativa | SC   | 2     | 16-Apr-24   |
| Acelyrin             | 22107           | Hidradenitis Suppurativa | SC   | 3     | 26-Feb-25   |
| Adelphi              | AB6762B         | Hidradenitis Suppurativa | SC   | OBS   | 01-Mar-25   |
| Boehringer Ingelheim | 1368-0098       | Hidradenitis Suppurativa | SC   | 2b/3  | 31-Jul-25   |
| Novartis             | CAIN457M2301E1  | Hidradenitis Suppurativa | SC   | 3     | 26-Aug-25   |
| Incyte               | INCB54707-302   | Hidradenitis Suppurativa | SC   | 3     | 23-Jan-26   |
| Incyte               | INCB54707-301   | Hidradenitis Suppurativa | SC   | 3     | 17-Feb-26   |
| Sanofi               | ACT17841        | Hidradenitis Suppurativa | SC   | 2     | 19-Feb-26   |
| Moonlake             | M1095-HS-304    | Hidradenitis Suppurativa | SC   | 3     | 21-May-26   |
| Incyte               | INCB054707-801  | Hidradenitis Suppurativa | SC   | 3b    | ONGOING     |
| Incyte               | INCB54707-312   | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Incyte               | INCB54707-312   | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Moonlake             | M1095-HS-301    | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Moonlake             | M1095-HS-303    | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Novartis             | CCFZ533H12201BC | Hidradenitis Suppurativa | SC   | 2     | ONGOING     |
| Novartis             | CLOU064J12301   | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Abbvie               | M20-262         | Hidradenitis Suppurativa | SC   | 2     | ONGOING     |
| Abbvie               | M20-465         | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Abbvie               | M23-698         | Hidradenitis Suppurativa | SC   | 3     | ONGOING     |
| Lilly                | I7P-MC-DSAF     | Hidradenitis Suppurativa | SC   | 2b    | ONGOING     |
| Merck                | MK7240-012      | Hidradenitis Suppurativa | SC   | 2b    | ONGOING     |
| Pfizer               | B7981119        | Hidradenitis Suppurativa | SC   | 2     | ONGOING     |
| Mayne                | 18-ICH-001      | Lamellar Ichthyosis      | SC   | 2     | 17-Jan-22   |
| Timber               | TMB01-301/MUST  | Lamellar Ichthyosis      | SC   | 3     | 03-Dec-24   |
| Priovant             | PVT-2201-304    | Lichen Planopilaris      | SC   | 2/3   | ONGOING     |
| Incyte               | INCB18424-216   | Lichen Planus            | SC   | 2     | 25-Apr-24   |
| Novartis             | CGIA362C12201   | Lichen Planus            | SC   | 2     | ONGOING     |
| Lilly                | I5V-MC-TSAT     | Low Testosterone         | SC   | 3     | 25-Jun-15   |
| Evidera              | EVA-36509-01    | Lower Abdominal Fat      | SC   | OBS   | 08-Nov-23   |
| Evidera              | EVA-36509-02    | Lower Abdominal Fat      | SC   | OBS   | 18-Jul-24   |
| Evidera              | EVA-36509-04    | Lower Abdominal Fat      | SC   | OBS   | 23-Jan-25   |
| Evidera              | EVA-36509-08    | Lower Abdominal Fat      | SC   | OBS   | 18-Sep-25   |
| Evidera              | 146323-01       | Lower Abdominal Fat      | SC   | OBS   | 01-Nov-25   |
| Evidera              | 152364-01       | Lower Abdominal Fat      | SC   | OBS   | 01-Jun-26   |
| Novan                | NI-MC201        | Molluscum Contagiosum    | SC   | 2     | 09-Jan-19   |
| Novan                | NI-MC301        | Molluscum Contagiosum    | SC   | 3     | 09-Jan-19   |
| DermTech             | 17-06           | Multi-Indication         | SC   | 4     | 17-Jun-24   |
| Lilly                | I1F-MC-B018     | Nail Psoriasis           | SC   | OBS   | 29-Jan-25   |
| Quoin                | CL-QRX003-001   | Netherton Syndrome       | SC   | 2     | 08-Apr-26   |
| BioCryst             | BCX17725-101    | Netherton Syndrome       | SC   | 1     | ONGOING     |

# Ashley N. Wallace, BS CCRC

| Sponsor         | Protocol            | Indication                          | Role | Phase | Date of COV |
|-----------------|---------------------|-------------------------------------|------|-------|-------------|
| Quoin           | CL-QRX003-002       | Netherton Syndrome                  | SC   | 2     | ONGOING     |
| Quoin           | CL-QRX003-004       | Netherton Syndrome                  | SC   | 3     | ONGOING     |
| Quoin           | CL-QRX003-005       | Netherton Syndrome                  | SC   | 3     | ONGOING     |
| Quoin           | CL-QRX003-006       | Netherton Syndrome                  | SC   | 3     | ONGOING     |
| DermTech        | 21-02               | Normal Skin                         | SC   | 4     | 29-Jan-24   |
| Mindera         | MND-24-MK-02        | Normal Skin                         | SC   | 1     | 30-Sep-25   |
| Evidera         | EVA-27657           | Notalgia Parasthetica               | SC   | OBS   | 18-Mar-21   |
| Cara            | CR845-210601        | Notalgia Parasthetica               | SC   | 2     | 11-Aug-22   |
| Evidera         | EVA-37056-00        | Notalgia Parasthetica               | SC   | OBS   | 24-Apr-24   |
| Cara            | CR845-310601        | Notalgia Parasthetica               | SC   | 2-3   | 02-Jul-24   |
| Clexio          | CLE400-NP-201       | Notalgia Parasthetica               | SC   | 2     | 24-Jan-25   |
| Hisamitsu       | HTU-520-US01        | Onychomycosis                       | SC   | 2     | 01-May-13   |
| XOMA            | X052160             | Osteoarthritis of the Hand          | SC   | 2     | 10-Apr-14   |
| XOMA            | X052162             | Osteoarthritis of the Hand          | SC   | 2     | 10-Apr-14   |
| XOMA            | X052161             | Osteoarthritis of the Hand          | SC   | 2     | 01-Jun-15   |
| Pfizer          | A3191172            | Osteoarthritis/Rheumatoid Arthritis | SC   | 4     | 19-Sep-16   |
| Novartis        | CAIN457A2312        | Palmoplantar Psoriasis              | SC   | 3b    | 03-Apr-17   |
| Abbvie          | M15-994             | Palmoplantar Psoriasis              | SC   | 3b    | 17-Jul-23   |
| BMS             | IM011-1112          | Palmoplantar Psoriasis              | SC   | 4     | 02-Jul-25   |
| AnaptysBio      | ANB019-003          | Palmoplantar Pustulosis             | SC   | 2     | 09-Jun-21   |
| Aristea         | RIST4721-202        | Palmoplantar Pustulosis             | SC   | 2     | 12-May-23   |
| Galderma        | RD.06.SPR.18171     | Papulopustular Rosacea              | SC   | 3     | 11-Sep-13   |
| Cutanea         | CLS001-CO-PR-001.01 | Papulopustular Rosacea              | SC   | 2     | 17-Apr-14   |
| Azitra          | CTAR-403            | Papulopustular Rosacea              | SC   | 1b/2a | 10-Jun-21   |
| Dr. Reddy's     | DFD-29-CD-004       | Papulopustular Rosacea              | SC   | 3     | 24-Jul-23   |
| Evidera         | EVA-20259           | Pediatric Psoriasis                 | SC   | OBS   | 01-Oct-18   |
| Sanofi          | EFC16459            | Prurigo Nodularis                   | SC   | 3     | 25-May-22   |
| Galderma        | RD.06.SPR.202699    | Prurigo Nodularis                   | SC   | 3     | 13-Jun-22   |
| Galderma        | RD.06.SPR.203065    | Prurigo Nodularis                   | SC   | 3     | 13-Jun-22   |
| Incyte          | INCB18424-110       | Prurigo Nodularis                   | SC   | 1     | 09-May-25   |
| InnoCare        | ICP-CL-00609        | Prurigo Nodularis                   | SC   | 2     | ONGOING     |
| Sanofi          | OBS17721            | Prurigo Nodularis                   | SC   | 4     | ONGOING     |
| Galderma        | SPR207807           | Prurigo Nodularis                   | SC   | OBS   | ONGOING     |
| Schering Plough | PO5495              | Psoriasis                           | SC   | 2     | 30-Jan-13   |
| Amgen           | 20040210            | Psoriasis                           | SC   | OBS   | 19-Feb-13   |
| Amgen           | 20040210            | Psoriasis                           | SC   | OBS   | 19-Feb-13   |
| Lilly           | I1F-MC-RHBL         | Psoriasis                           | SC   | 3     | 03-Oct-13   |
| Janssen         | CNT01959PSO2001     | Psoriasis                           | SC   | 2     | 01-Nov-13   |
| GSK             | 200851              | Psoriasis                           | SC   | 3     | 01-Dec-13   |
| Pfizer          | A3921078            | Psoriasis                           | SC   | 3     | 06-Jan-14   |
| Amgen           | HRA1889A            | Psoriasis                           | SC   | OBS   | 20-Aug-14   |
| Novartis        | CAIN457A2223        | Psoriasis                           | SC   | 2     | 08-May-15   |
| Celgene         | CC-10004-PSOR-010   | Psoriasis                           | SC   | 3b    | 15-Jul-15   |
| Pfizer          | B7451005            | Psoriasis                           | SC   | 2     | 02-Sep-15   |

# Ashley N. Wallace, BS CCRC

| Sponsor              | Protocol            | Indication | Role | Phase | Date of COV |
|----------------------|---------------------|------------|------|-------|-------------|
| Maruho               | M518101-US02        | Psoriasis  | SC   | 3     | 11-Sep-15   |
| Amgen                | 20120104            | Psoriasis  | SC   | 3     | 22-Dec-15   |
| Janssen              | 38515168PSO2001     | Psoriasis  | SC   | 2     | 13-Jan-16   |
| Novartis             | CCJM112X2101        | Psoriasis  | SC   | 1     | 26-Jan-16   |
| Amgen                | HRA1603A (20130126) | Psoriasis  | SC   | OBS   | 11-Feb-16   |
| Galderma             | RD.06.SPR.18104     | Psoriasis  | SC   | 4     | 25-Feb-16   |
| Amgen                | 20101177            | Psoriasis  | SC   | 4     | 18-Mar-16   |
| Evidera              | EVA-18225           | Psoriasis  | SC   | OBS   | 02-Jun-16   |
| Tolmar               | TOL2707A            | Psoriasis  | SC   | 3     | 02-Jun-16   |
| Janssen              | CNT01959PSO3003     | Psoriasis  | SC   | 3     | 19-Jul-16   |
| Sandoz               | GP17-301            | Psoriasis  | SC   | 3     | 24-Jul-16   |
| Evidera              | EVA-18225-01        | Psoriasis  | SC   | OBS   | 03-Aug-16   |
| Promius              | DFD06-CD-005        | Psoriasis  | SC   | 3     | 29-Aug-16   |
| Celgene              | CC-10004-PSOR-008   | Psoriasis  | SC   | 3     | 06-Oct-16   |
| Pfizer               | A3921061            | Psoriasis  | SC   | 3     | 11-Oct-16   |
| Novartis             | CAIN457A2317        | Psoriasis  | SC   | 3b    | 19-Nov-16   |
| Novartis             | CAIN457A2313        | Psoriasis  | SC   | 3b    | 04-Apr-17   |
| Novartis             | CAIN457A2303        | Psoriasis  | SC   | 3     | 04-Apr-17   |
| Amgen                | 20120363            | Psoriasis  | SC   | OBS   | 12-Apr-17   |
| Lilly                | I1F-MC-RHBP         | Psoriasis  | SC   | 3     | 07-Jun-17   |
| UCB                  | PS0010              | Psoriasis  | SC   | 2b    | 12-Jun-17   |
| BMS                  | IM011-011           | Psoriasis  | SC   | 2     | 23-Aug-17   |
| Stiefel              | STF115750           | Psoriasis  | SC   | 1     | 30-Aug-17   |
| Janssen              | CNT01275PSO3013     | Psoriasis  | SC   | 3     | 05-Oct-17   |
| Baxalta              | 911401              | Psoriasis  | SC   | 3     | 24-Oct-17   |
| Novartis             | CAIN457A2304        | Psoriasis  | SC   | 3     | 25-Oct-17   |
| Novartis             | CAIN457A2304E1      | Psoriasis  | SC   | 3     | 25-Oct-17   |
| Novartis             | CAIN457A2302E1      | Psoriasis  | SC   | 3     | 18-Nov-17   |
| Boehringer Ingelheim | 1311.28             | Psoriasis  | SC   | 3     | 21-Nov-17   |
| Sun Pharmaceuticals  | 71542611            | Psoriasis  | SC   | 3     | 16-Feb-18   |
| UCB                  | PS0003              | Psoriasis  | SC   | 3     | 01-Apr-18   |
| Pfizer               | B7931004            | Psoriasis  | SC   | 2a    | 08-May-18   |
| Pfizer               | B7931004            | Psoriasis  | SC   | 2a    | 08-May-18   |
| Allergan             | 1957-201-001        | Psoriasis  | SC   | 2b    | 22-May-18   |
| Galderma             | RD.06.SPR.18131     | Psoriasis  | SC   | 4     | 29-Aug-18   |
| Novartis             | CAIN457A2326        | Psoriasis  | SC   | 3     | 26-Sep-18   |
| Janssen              | CNT01959PSO3009     | Psoriasis  | SC   | 3     | 30-Oct-18   |
| Novartis             | CAIN457A2310        | Psoriasis  | SC   | 3     | 31-Oct-18   |
| Boehringer Ingelheim | 1297.9              | Psoriasis  | SC   | 3     | 01-Jan-19   |
| Lilly                | I1F-MC-RHAZ         | Psoriasis  | SC   | 3     | 23-Jan-19   |
| Sienna               | SNA-120-202         | Psoriasis  | SC   | 2     | 01-Feb-19   |
| Dermira              | PS0003              | Psoriasis  | SC   | 3     | 13-Mar-19   |
| Dr. Reddy's          | PPC-06-CD-004       | Psoriasis  | SC   | 2     | 28-May-19   |
| Novartis             | CAIN457AUS07        | Psoriasis  | SC   | 4     | 03-Jun-19   |

# Ashley N. Wallace, BS CCRC

| Sponsor              | Protocol          | Indication | Role | Phase | Date of COV |
|----------------------|-------------------|------------|------|-------|-------------|
| Lilly                | I7P-MC-DSAB       | Psoriasis  | SC   | 1     | 29-Aug-19   |
| Lilly                | I7P-MC-DSAB       | Psoriasis  | SC   | 1     | 29-Aug-19   |
| Kadmon               | KD025-211         | Psoriasis  | SC   | 2     | 07-Nov-19   |
| Lilly                | I1F-MC-RHBC       | Psoriasis  | SC   | 3     | 17-Dec-19   |
| Merck                | MK3222-010        | Psoriasis  | SC   | 3     | 28-Jan-20   |
| Akros                | AE451-G-18-004    | Psoriasis  | SC   | 2/3   | 12-May-20   |
| Dermavant            | DMVT-505-3001     | Psoriasis  | SC   | 3     | 22-Jul-20   |
| Lilly                | I6T-MC-AMAJ       | Psoriasis  | SC   | 3     | 22-Jul-20   |
| Lilly                | I1F-MC-RHCR       | Psoriasis  | SC   | 4     | 23-Jul-20   |
| Janssen              | CNT01959PSO3002   | Psoriasis  | SC   | 3     | 10-Sep-20   |
| Celgene              | CC-10004-PSOR-022 | Psoriasis  | SC   | 3     | 22-Oct-20   |
| Novartis             | CAIN457A2324      | Psoriasis  | SC   | 3b    | 10-Nov-20   |
| Arcutis              | ARQ-154-204       | Psoriasis  | SC   | 2b    | 02-Dec-20   |
| BMS                  | IM011-047         | Psoriasis  | SC   | 3     | 19-Jan-21   |
| Arcutis              | ARQ-151-302       | Psoriasis  | SC   | 3     | 31-Mar-21   |
| Arcutis              | ARQ-151-306       | Psoriasis  | SC   | 3     | 28-Apr-21   |
| GSK                  | 200853            | Psoriasis  | SC   | 3     | 01-May-21   |
| Dermavant            | DMVT-505-3003     | Psoriasis  | SC   | 2/3   | 08-Jun-21   |
| Boehringer Ingelheim | 1407-0030         | Psoriasis  | SC   | 2     | 22-Jul-21   |
| Lilly                | I6T-MC-AMBK       | Psoriasis  | SC   | 2/3   | 28-Jul-21   |
| Boehringer Ingelheim | 1407-0005         | Psoriasis  | SC   | 2     | 21-Oct-21   |
| Lilly                | F1P-MC-KFAC       | Psoriasis  | SC   | 1     | 03-Nov-21   |
| Lilly                | I6T-MC-AMAH       | Psoriasis  | SC   | 3     | 28-Apr-22   |
| Amgen                | 20190232          | Psoriasis  | SC   | 3     | 08-Sep-22   |
| Janssen              | 77242113PSO2001   | Psoriasis  | SC   | 2b    | 28-Sep-22   |
| Abbvie               | M19-164           | Psoriasis  | SC   | 3b    | 29-Sep-22   |
| Abbvie               | M19-164 Companion | Psoriasis  | SC   | 3b    | 29-Sep-22   |
| Aurigene             | AUR101-202        | Psoriasis  | SC   | 2     | 12-Oct-22   |
| Arcutis              | ARQ-151-311       | Psoriasis  | SC   | 3     | 08-Nov-22   |
| Nimbus               | 4858-201          | Psoriasis  | SC   | 2b    | 05-Dec-22   |
| Biocon               | BIO-USTEKI-305    | Psoriasis  | SC   | 3     | 20-Dec-22   |
| Janssen              | 77242113PSO2002   | Psoriasis  | SC   | 2b    | 23-Jan-23   |
| Abbvie               | M15-997           | Psoriasis  | SC   | 3     | 20-Mar-23   |
| Abbvie               | M18-816           | Psoriasis  | SC   | 2     | 20-Mar-23   |
| Abbott               | P10-023           | Psoriasis  | SC   | OBS   | 28-Mar-23   |
| Abbott               | P10-023           | Psoriasis  | SC   | OBS   | 28-Mar-23   |
| PSOLAR               | C0168Z03          | Psoriasis  | SC   | OBS   | 18-May-23   |
| Abbvie               | M20-326           | Psoriasis  | SC   | 4     | 17-Jul-23   |
| Celgene              | CC-10004-PPSO-003 | Psoriasis  | SC   | 3     | 03-Aug-23   |
| Biocon               | BM12H-PSO-03-G-02 | Psoriasis  | SC   | 3     | 11-Jan-24   |
| Ventyx               | VTX958-201        | Psoriasis  | SC   | 2     | 13-Feb-24   |
| Janssen              | 77242113PSO3001   | Psoriasis  | SC   | 3     | 19-Mar-24   |
| DICE Therapeutics    | DCE806201         | Psoriasis  | SC   | 2     | 28-Mar-24   |
| Mindera              | MND-21-MKPs-02    | Psoriasis  | SC   | 4     | 28-May-24   |

# Ashley N. Wallace, BS CCRC

| Sponsor              | Protocol          | Indication           | Role | Phase | Date of COV |
|----------------------|-------------------|----------------------|------|-------|-------------|
| LITE                 | PCS-1608-35830    | Psoriasis            | SC   | 2/3   | 05-Jul-24   |
| UCB                  | PS0020            | Psoriasis            | SC   | 2     | 17-Jul-24   |
| Sanofi               | DRI17849          | Psoriasis            | SC   | 2     | 03-Dec-24   |
| Janssen              | 77242113PSO3003   | Psoriasis            | SC   | 3     | 14-Jan-25   |
| Janssen              | 77242113PSO3002   | Psoriasis            | SC   | 3     | 20-Feb-25   |
| BMS                  | IM011-075         | Psoriasis            | SC   | 3b    | 06-May-25   |
| Janssen              | CNTO1959PSO3018   | Psoriasis            | SC   | 3b    | 10-Sep-25   |
| Takeda               | TAK279-3001       | Psoriasis            | SC   | 3     | 20-Jan-26   |
| Alumis               | ESK-001-016       | Psoriasis            | SC   | 3     | 17-Feb-26   |
| Dermavant            | DMVT-505-3004     | Psoriasis            | SC   | 3     | 11-Mar-26   |
| Celgene              | CC-10004-PPSO-004 | Psoriasis            | SC   | 3b    | 24-Mar-26   |
| Takeda               | TAK-279-PsO-3004  | Psoriasis            | SC   | 3     | 02-Jun-26   |
| Abbvie               | M24-541           | Psoriasis            | SC   | 4     | 02-Jun-26   |
| Alumis               | ESK-001-018       | Psoriasis            | SC   | 3     | ONGOING     |
| InventisBio          | D2570-207         | Psoriasis            | SC   | 2     | ONGOING     |
| Takeda               | TAK279-3003       | Psoriasis            | SC   | 3     | ONGOING     |
| Amgen                | 20200196          | Psoriasis            | SC   | 3     | ONGOING     |
| BMS                  | IM011-1128        | Psoriasis            | SC   | 3     | ONGOING     |
| BMS                  | IM011-1130        | Psoriasis            | SC   | 3b/4  | ONGOING     |
| CorEvitas            | CorEvitas-PSO-505 | Psoriasis            | SC   | OBS   | ONGOING     |
| Corrona              | Corrona-PSO-550   | Psoriasis            | SC   | 4     | ONGOING     |
| Lilly                | I1F-MC-RHDC       | Psoriasis            | SC   | 3b    | ONGOING     |
| Lilly                | I1F-MC-RHDD       | Psoriasis            | SC   | 3b    | ONGOING     |
| UCB                  | PS0021            | Psoriasis            | SC   | 3     | ONGOING     |
| UPENN                | CP3               | Psoriasis            | SC   | 4     | ONGOING     |
| AbGenomics           | 2012.005.01       | Psoriasis            | SC   | 2a    | 15-Apr-14   |
| AbGenomics           | 2014.002.01       | Psoriasis            | SC   | 2     | 09-Apr-15   |
| Abcentra             | ORT-2020-01       | Psoriasis            | SC   | 2     | 21-Feb-23   |
| Janssen              | CNTO1275PSA3002   | Psoriatic Arthritis  | SC   | 3     | 17-Jan-13   |
| Janssen              | CNTO1275PSA3001   | Psoriatic Arthritis  | SC   | 3     | 06-Aug-13   |
| Janssen              | CNTO148PSA3001    | Psoriatic Arthritis  | SC   | 3     | 08-Sep-15   |
| Janssen              | CNTO1959PSA2001   | Psoriatic Arthritis  | SC   | 2a    | 01-Mar-17   |
| Abbvie               | H15-457           | Psoriatic Arthritis  | SC   | OBS   | 25-Oct-17   |
| Janssen              | CNTO1959PSA3001   | Psoriatic Arthritis  | SC   | 3     | 10-Jul-18   |
| Janssen              | CNTO1959PSA3002   | Psoriatic Arthritis  | SC   | 3     | 10-Jul-18   |
| Novartis             | CAIN457F2318      | Psoriatic Arthritis  | SC   | 3     | 06-Sep-18   |
| Novartis             | CAIN457P12302     | Psoriatic Arthritis  | SC   | 3     | 12-Sep-22   |
| Nimbus               | 4858-202          | Psoriatic Arthritis  | SC   | 2b    | 29-Mar-23   |
| Novartis             | CAIN457A02001B    | Psoriatic Arthritis  | SC   | 4     | 23-Jan-25   |
| Boehringer Ingelheim | 1368-0140         | Pyoderma Gangrenosum | SC   | 3     | ONGOING     |
| Merck                | MK-0663-107       | Rheumatoid Arthritis | SC   | 3     | 29-Jul-14   |
| Perrigo              | PRG-NY-14-022     | Rosacea              | SC   | 3     | 17-Nov-15   |
| Cutanea              | CLS001-CO-PR-006  | Rosacea              | SC   | 3     | 07-Mar-18   |
| Evidera              | EVA-20371-01      | Scalp Psoriasis      | SC   | OBS   | 11-Jan-24   |

# Ashley N. Wallace, BS CCRC

| Sponsor    | Protocol         | Indication            | Role | Phase | Date of COV |
|------------|------------------|-----------------------|------|-------|-------------|
| BMS        | IM011-220        | Scalp Psoriasis       | SC   | 3b/4  | 19-Nov-24   |
| Arcutis    | ARQ-154-304      | Seborrheic Dermatitis | SC   | 3     | 06-Jul-22   |
| Evidera    | EVA-44850        | Skin Tone Assessment  | SC   | OBS   | ONGOING     |
| Merck      | 009-00           | Vaccine               | SC   | 2     | 26-Feb-13   |
| RXI        | RXI-SCP-1502     | Verruca Vulgaris      | SC   | 2a    | 06-Sep-18   |
| Incyte     | INCB18424-211    | Vitiligo              | SC   | 2     | 28-Aug-20   |
| DRG Abacus | 8493             | Vitiligo              | SC   | OBS   | 01-Dec-20   |
| Evidera    | EVA-31203-01     | Vitiligo              | SC   | OBS   | 31-Oct-22   |
| Abbvie     | M19-051          | Vitiligo              | SC   | 2     | 09-Nov-23   |
| Merck      | MK-6194-007      | Vitiligo              | SC   | 2a    | 20-May-25   |
| VYNE       | VY2024-02        | Vitiligo              | SC   | 2b    | 30-Jul-25   |
| Pfizer     | B7981080         | Vitiligo              | SC   | 3     | 10-Sep-25   |
| Pfizer     | B7981040         | Vitiligo              | SC   | 3     | 05-Mar-26   |
| Novartis   | CGIA362B12201    | Vitiligo              | SC   | 2     | ONGOING     |
| Abbvie     | M19-044          | Vitiligo              | SC   | 3     | ONGOING     |
| Abbvie     | M25-264          | Vitiligo              | SC   | 3     | ONGOING     |
| Lilly      | J5D-MC-FPAD      | Vitiligo              | SC   | 2     | ONGOING     |
| Pfizer     | B7981041         | Vitiligo              | SC   | 3     | ONGOING     |
| Aclaris    | A-101-WART-202   | Warts                 | SC   | 2     | 11-Apr-18   |
| Cutanea    | CLS006-CO-PR-002 | Warts                 | SC   | 3     | 22-Jan-19   |
| Aclaris    | A-101-WART-301   | Warts                 | SC   | 3     | 26-Nov-19   |
| Aclaris    | A-101-WART-303   | Warts                 | SC   | 3     | 29-Jan-20   |